Chardan Capital upgraded shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) from a neutral rating to a buy rating in a research report released on Friday, Marketbeat.com reports. They currently have $140.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $60.00.

Several other equities analysts also recently weighed in on SAGE. Raymond James Financial, Inc. lifted their target price on Sage Therapeutics to $109.00 and gave the company a buy rating in a research report on Thursday. Stifel Nicolaus lifted their target price on Sage Therapeutics from $91.00 to $105.00 and gave the company a buy rating in a research report on Thursday. Needham & Company LLC set a $95.00 target price on Sage Therapeutics and gave the company a buy rating in a research report on Friday, August 4th. Leerink Swann boosted their price objective on Sage Therapeutics from $85.00 to $123.00 and gave the stock a positive rating in a research report on Thursday. Finally, HC Wainwright boosted their price objective on Sage Therapeutics to $86.00 and gave the stock a neutral rating in a research report on Friday, August 4th. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $99.86.

Shares of Sage Therapeutics (NASDAQ SAGE) traded down $0.61 on Friday, reaching $96.04. 1,750,000 shares of the company traded hands, compared to its average volume of 783,192. Sage Therapeutics has a 12-month low of $44.55 and a 12-month high of $98.80.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($1.98) by $0.01. The firm’s quarterly revenue was up .0% compared to the same quarter last year. equities analysts predict that Sage Therapeutics will post -7.36 earnings per share for the current year.

WARNING: “Sage Therapeutics, Inc. (SAGE) Lifted to Buy at Chardan Capital” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/sage-therapeutics-inc-sage-lifted-to-buy-at-chardan-capital/1701026.html.

Institutional investors have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board purchased a new stake in shares of Sage Therapeutics during the second quarter worth approximately $1,991,000. Teacher Retirement System of Texas acquired a new position in Sage Therapeutics during the second quarter worth $202,000. Schwab Charles Investment Management Inc. grew its holdings in Sage Therapeutics by 1.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 131,440 shares of the biopharmaceutical company’s stock worth $9,342,000 after acquiring an additional 1,593 shares during the period. Rhumbline Advisers grew its holdings in Sage Therapeutics by 9.4% during the second quarter. Rhumbline Advisers now owns 41,138 shares of the biopharmaceutical company’s stock worth $3,276,000 after acquiring an additional 3,551 shares during the period. Finally, Amalgamated Bank acquired a new position in Sage Therapeutics during the first quarter worth $262,000.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.